Lack of effect of a new spasmolytic agent, rociverine, on intraocular pressure, pupil size and iridocorneal angle in patients with angle-closure glaucoma.
Twenty patients with angle-closure glaucoma (38 glaucomatous eyes - 17 surgically operated, 21 non-operated) were treated with rociverine (60 mg orally per day for 7 days), a new direct myolitic and mildly anticholinergic antispasmodic drug. Intraocular pressure, pupil size, iridocorneal angle, blood pressure and heart rate were checked before and during treatment. No clinically significant variations were observed in the parameters tested. It is suggested, therefore, that rociverine may be administered, if necessary, even to patients with angle-closure glaucoma.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D003509:Cyclohexanecarboxylic Acids; D005260:Female; D005901:Glaucoma; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000494:pharmacology*; D011680:Pupil / Q000187:drug effects*; D013997:Time Factors
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D003509:Cyclohexanecarboxylic Acids; D010276:Parasympatholytics; C021082:rociverine